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Increasing lines of evidence support that testosterone may have neuroprotective effects. While observational studies reported an
association between higher bioavailable testosterone or brain testosterone levels and reduced risk of Alzheimer’s disease (AD),
there is limited understanding of the underlying neuroprotective mechanisms. Previous studies demonstrated that testosterone
could alleviate neurotoxicity induced by 𝛽-amyloid (A𝛽), but these findings mainly focused on neuronal apoptosis. Since synaptic
dysfunction and degeneration are early events during the pathogenesis of AD, we aim to investigate the effects of testosterone on
oligomericA𝛽-induced synaptic changes.Our data suggested that exposure of primary cultured hippocampal neurons to oligomeric
A𝛽 could reduce the length of neurites and decrease the expression of presynaptic proteins including synaptophysin, synaptotagmin,
and synapsin-1. A𝛽 also disrupted synaptic vesicle recycling and protein folding machinery. Testosterone preserved the integrity
of neurites and the expression of presynaptic proteins. It also attenuated A𝛽-induced impairment of synaptic exocytosis. By using
letrozole as an aromatase antagonist, we further demonstrated that the effects of testosterone on exocytosis were unlikely to be
mediated through the estrogen receptor pathway. Furthermore, we showed that testosterone could attenuate A𝛽-induced reduction
of HSP70, which suggests a novel mechanism that links testosterone and its protective function on A𝛽-induced synaptic damage.
Taken together, our data provide further evidence on the beneficial effects of testosterone, which may be useful for future drug
development for AD.
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1. Introduction
Cognitive dysfunction or impairment is the major symptom
inAlzheimer’s disease (AD). Loss of synaptic proteins leading
to synaptic dysfunctions and perturbation of cytoskeleton
leading to disturbance of axonal transport may explain the
underlying mechanisms of these cognitive changes [1, 2].
Neurotransmission is a complicated process which involves
multiple steps: synthesis and storage of neurotransmitter in
synaptic vesicles, transmission of synaptic vesicles towards
presynaptic density membrane, docking of synaptic vesicles
to presynaptic membrane, release of neurotransmitter, reup-
take of excessive neurotransmitters, and recycling of synap-
tic vesicles [3]. These processes must be highly regulated.
Dysfunction of any of the above steps will impair normal
neurotransmission, which is indeed a major pathological
change during the progression ofAD [4–6]. It has been shown
that oligomeric 𝛽-amyloid (A𝛽) peptide can impair both
presynaptic and postsynaptic density proteins and receptors
for neurotransmitters in experimental models of AD [7–
10]. Preventing the deterioration of synaptic degeneration
is therefore an important therapeutic approach to delay the
progression of AD.
The reduction of bioavailable testosterone is associated
with increased levels of A𝛽 peptides, hyperphosphorylation
of tau protein, and neuronal cell death. Therefore, the loss of
bioavailable testosterone and its metabolites dihydrotestos-
terone or estrogen has been suggested as a risk factor of
developing dementia and evenAD [11–14].The significance of
testosterone in the development of AD has been extensively
investigated by Pike’s laboratory.They reported that androgen
regulates A𝛽 levels via androgen receptor (AR) and estrogen
receptor (ER) in cell cultures and rodent AD models [15].
Testosterone had been shown to increase neuronal viability
in cultured hippocampal neurons through the AR-dependent
mitogen-activated protein kinase (MAPK)/extracellular sig-
nal related kinase (ERK) signaling pathway [16]. Testosterone
could also elevate the levels of neprilysin to facilitate A𝛽
clearance [17]. Furthermore, it was found that the nonarom-
atizable androgen dihydrotestosterone (DHT), which is con-
verted from testosterone, exerted neuroprotective effects by
activating the AR-dependent cyclic AMP response element
binding protein (CREB) signaling pathway in PC12 cells and
cultured hippocampal neurons [18]. Evidence in AD mice
models showed thatDHT elevated the levels of neprilysin and
reduced A𝛽 levels via AR-independent pathway [19, 20]. A
more recent finding further demonstrated that testosterone
promoted the degradation of A𝛽 through an estrogenic
pathway-independent manner [21]. All these data suggested
that physiological level of testosterone is likely to reduce the
chance of developing AD.
Preventing the loss or degeneration of synapse at early
phase of AD is important [1, 22]. Since it has been suggested
that testosterone is neuroprotective and prevents neurode-
generation, it is reasonable to speculate that testosterone
may elicit a protective role in synapse. It has been well
reported that synaptic vesicle proteins play a curial role in
neurotransmission, and synaptic vesicle proteins recycling
was decreased by oligomeric A𝛽 [9, 23]. Heat shock proteins
are chaperones that help in preventing protein aggregation
and fighting against cellular stress and thus have a potential
implication for neurodegenerative disorders [24, 25]. HSP70
and HSP90 were found to suppress A𝛽 aggregation in vitro
[26]. A study using humanneurons reported that testosterone
increased HSP70 protein levels and consequently attenuated
A𝛽 toxicity [27]. In the present study, we aim to investi-
gate whether testosterone can prevent synaptic degeneration
triggered by oligomeric A𝛽 peptide. We demonstrate that
physiological level of testosterone reversed A𝛽-induced neu-
rite damage, loss of synaptic vesicle proteins, and exocytosis
dysfunction.The synaptoprotective effects of testosterone are
accomplished by an ER-independent pathway.
2. Materials and Methods
2.1. Animals. Animal experimental protocol was approved by
the Committee on the Use of Live Animals in Teaching and
Research of The University of Hong Kong. The Laboratory
Animal Unit of The University of Hong Kong is accredited
by the Association for Assessment and Accreditation for
Laboratory Animal Care (AAALAC International).
2.2. Primary Cultures of Rat Hippocampal Neurons. Primary
cultures of rat hippocampal neurons were prepared from
embryonic day 18 Sprague-Dawley rat embryos by using the
method described previously [28]. Briefly, hippocampi were
dissected in 1X PBS supplemented with glucose (18mM).
They were then mechanically dissociated in minimum
essential medium (MEM) and then seeded onto poly-L-
lysine (25 𝜇g/mL) coated 15mm glass coverslips at density
of 7 × 104 cells/coverslip in neurobasal medium contain-
ing 2% B-27, glutamax (2mM), penicillin (50U/mL), and
streptomycin (50𝜇g/mL) (Gibco-BRL). Deoxyfluorouridine
(dFUR) (Sigma) was added into the neuronal cultures at
day in vitro 2 (DIV 2) at a final concentration of 1𝜇M for
inhibiting proliferating glial cells.Hippocampal neuronswere
cultured for 14 days at 37∘C in a humidified 5%CO
2
incubator
prior to treatment. All treatments were performed in DIV
14 hippocampal neurons. We chose this developmental stage
because it had been shown that neurons developed all
synaptic components such as synaptic proteins and spine after
2 weeks of culture [29, 30].
2.3. Oligomeric A𝛽 Peptides Preparation and Treatment. Oli-
gomeric A𝛽 was prepared according to our previous report
[31]. A𝛽
1–42 peptide was dissolved in 1,1,1,3,3,3-hexafluoro-2-
propanol (Sigma) and then it was dried overnight by air at
room temperature. The peptide pellet was resuspended with
anhydrous DMSO (Sigma) at 2mM as final concentration.
A𝛽 was then bath-sonicated for 30min at room temperature.
Aliquot A𝛽 peptide was stored at −80∘C deep freezer before
use. The working concentration of A𝛽 was 5 𝜇M in all
experiments.This concentration of A𝛽 could induce synaptic
degeneration including the reduction of synaptic proteins but
not apoptosis when applied to hippocampal neurons for 24 h
[28, 31].
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To investigate the neurotoxicity of A𝛽 on primary cul-
tures of hippocampal neurons, A𝛽 was diluted with NB
medium and was added to the cell culture at DIV14 for
24 h. Neuroprotective effects of testosterone were investi-
gated in pretreatment experiments. 10 nM of testosterone has
been considered to be at physiological dose [32]. Previous
reports showed that 10 nM testosterone elicited neuroprotec-
tive effects in primary neuronal cultures [33, 34]. Based on
these findings, hippocampal neurons were incubated with
10 nM of testosterone (Sigma) for 1 h and then cotreated with
oligomeric A𝛽 for 24 h. The control group was treated with
DMSO as vehicle.
2.4. Immunocytochemistry. Immunocytochemical staining
was performed according to our previous publication [35].
Primary cultures of hippocampal neurons were fixed with
4% paraformaldehyde for 20min and then permeabilized
with 0.1% Triton X-100 for 7min at room temperature.
Nonspecific binding of antibody was blocked with 5% bovine
serum albumin (BSA) for 1 h. Neurons were incubated
with primary antibodies MAP-2, synapsin-1 (1 : 400; Cell
Signaling Technology), synaptophysin (1 : 400; Chemicon),
synaptotagmin (1 : 400; Calbiochem), and HSP70 (1 : 400;
Enzo life sciences) for 1 h. The neurons were washed with
TBS and then incubated with secondary antibodies (Alexa-
488; 1 : 400; Molecular Probes, Invitrogen) for 1 h at room
temperature. Neurons were washed with TBS and finally
mounted with ProLong Antifade Kit (Molecular Probes,
Invitrogen). Immunostaining was analyzed using a Carl Zeiss
LSM700 inverted confocal microscopy provided by Faculty
Core Facility, HKU.
2.5. Detection of the Loading and Unloading Capability of
Synaptic Vesicles by Using FM4-64 . The loading and unload-
ing capacity of synaptic vesicles was determined by using
FM4-64 probe (Molecular Probes, Invitrogen), which is a
modified styryl dye widely used for the visualization of
vacuoles and endocytic movement. The FM4-64 protocol
was adopted and modified from previous publication [36].
For the measurement of synaptic vesicles loading capacity,
FM probe (5 𝜇M) in HBSS was added to the neuronal
cultures after drug treatment. Potassium chloride (100mM)
was added simultaneously to stimulate the neurons to induce
endocytosis for 5min. After rinsing with HBSS, the neurons
were fixed with 4% paraformaldehyde and mounted with
ProLong Antifade Kit and images were captured by Carl
Zeiss LSM-510Meta/Axiocam inverted confocal microscope.
Similar procedures were carried out for the measurement
of synaptic vesicles unloading capability. After rinsing with
HBSS, the neurons were further incubated with potassium
chloride (100mM) for 5min to induce complete exocytosis.
The cultured neuronswere thenwashedwithHBSS to remove
potassium chloride, fixed with 4% paraformaldehyde, and
mounted and representative images were captured by the
confocal microscope.
2.6. Statistical Analysis. One-way analysis of variance
(ANOVA) was used to analyze the data for multiple variable
comparisons. Student-Newman-Keuls test was used as a post
hoc test. GraphPad Prism was used as the statistical software.
Results were expressed in fold of control and are shown as
mean ± standard error (SE) from at least three independent
experiments. In each experiment, at least 5 fields were
captured and 5 cells were counted in each treatment group.
3. Results
3.1. Testosterone Prevented Oligomeric A𝛽-Induced Neuritic
Damage and Synaptic Vesicle Proteins Disruption in Hip-
pocampal Neurons. To study the effects of testosterone
against A𝛽-induced damage on neurites, immunostain-
ing of microtubule-associated protein-2 (MAP-2) was per-
formed. Exposure of hippocampal neurons (DIV 14) to A𝛽
caused fragmentation of neurites and reduced their length
(Figure 1(c)) when compared to the control (Figure 1(a)). Pre-
treatment of neurons with testosterone for 1 h attenuated the
damaging effects of A𝛽 on neurites. As shown in Figure 1(d),
there were less fragmented neurites and the architecture of
neurites has been preserved. In order to examine the pro-
tective effects of testosterone against A𝛽 in synaptic regions,
immunocytochemical staining of synaptic vesicle proteins
including synaptophysin, synaptotagmin, and synapsin-1 was
conducted. As shown in Figures 2(a), 3(a), and 4(a), synap-
tophysin, synaptotagmin, and synapsin-1 were shown as fine
puncta along neurites in the control groups, respectively.The
number of puncta and fluorescent intensity of synaptophysin,
synaptotagmin, and synapsin-1 were markedly decreased
after A𝛽 treatment (Figures 2(c), 3(c), and 4(c)). The toxic
effects ofA𝛽were reversed by exposing hippocampal neurons
to testosterone for 1 h (Figures 2(d), 3(d), and 3(d)). Statis-
tical analysis showed that the pretreatment of testosterone
significantly elevated A𝛽-induced reduction of the number
of puncta and fluorescent intensity of synaptophysin and
synaptotagmin (Figures 2(e), 2(f), 3(e), and 3(f)). Testos-
terone also provided protection on synapsin-1, although it
is not statistically significant. All these data suggested that
testosterone reduced A𝛽-mediated synaptic damage and it
preserved synaptic vesicle proteins.
3.2. Testosterone Reversed Oligomeric A𝛽-Induced Exocyto-
sis Dysfunction. Neurotransmission within synapses can be
affected by membrane receptors, ion channels, endocyto-
sis, and exocytosis. In this study, FM fluorescent probe
was applied to the neurons to examine the loading and
unloading function of synaptic vesicles.Thefluorescent probe
was successfully uptaken by synaptic vesicles in all groups
(Figures 5(a)–5(d)). There was no significant difference in
fluorescent intensity between A𝛽-treated group and control
group in FM probe loading experiment (Figure 5 (k)), sug-
gesting that endocytosis was not affected by A𝛽 peptide.
On the other hand, the neuroprotective effects of testos-
terone were revealed in FM probe unloading experiment.
Aggregation of the FM probe was found in A𝛽-treated
neurons (Figure 5(g)), suggesting that A𝛽 caused impair-
ment of the exocytosis process, and hence FM probe could
not be released. However, when neurons were exposed
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Figure 1: Testosterone reduced neurite shortening following oligomeric A𝛽 treatment in primary hippocampal neurons. Primary
hippocampal neurons were treated with 10 nM testosterone for 1 h, followed by exposure to 5𝜇M oligomeric A𝛽 for 24 h. Neurons were
stained with MAP-2 antibody. (a) Control, (b) 10 nM testosterone for 25 h, (c) 5 𝜇MA𝛽 for 24 h, and (d) 10 nM testosterone for 1 h, followed
by exposure to 5 𝜇MA𝛽 for 24 h. Arrows indicate fragmentation of neurites and white dot boxes indicate shortening of neurites.
to testosterone for 1 h prior to A𝛽, the aggregation of FM
probewas significantly reduced comparedwith those without
testosterone (Figure 5(h)). To investigate the neuroprotective
effects of testosterone after blocking of the estrogenic path-
way, an aromatase antagonist letrozole (1 𝜇M) was used for
further experiments [37]. When neurons were exposed to
testosterone and letrozole for 1 h followed by exposure to A𝛽
for 24 h, FM probe fluorescent intensity was also significantly
lower than that of the A𝛽-treated group (Figure 5(l)). The
results suggested that A𝛽-induced exocytosis dysfunction
could be restored by testosterone probably through an
estrogenic-independent pathway.
3.3. Testosterone Retained Heat Shock Protein in Neurons
under A𝛽 Insults. Heat shock proteins are molecular chaper-
ones that play important regulatory roles for the stabilizing
and even facilitate the clearance misfolded or aggregated
proteins via chaperone-mediated autophagy. This is partic-
ularly important for the turnover of presynaptic proteins.
The fluorescent intensity of HSP70 was tremendously
decreased in A𝛽-treated neurons when compared with neu-
rons in the control group (Figures 6(a) and 6(c)). For neurons
exposed to testosterone prior to A𝛽, the fluorescent intensity
of HSP70 was markedly restored (Figure 6(d)). Analysis of
images showed that the level of HSP70 in testosterone treated
group was even similar to the control group (Figure 6(e)).
4. Discussion
Themale sex hormone testosterone has demonstrated its neu-
roprotective effects in various studies [38–40]. In AD, testos-
terone has been shown to improve neuronal viability and
reduce A𝛽 accumulation and AD-like pathological changes
in animal and cell culture models [34, 41]. Based on these
findings, we are interested to further explore the potential
protective effects of testosterone against A𝛽 neurotoxicity.
Specifically, we aim to examine its effects on oligomeric
A𝛽-induced synaptic changes. We found that testosterone
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Figure 2: Testosterone attenuated oligomeric A𝛽-induced reduction of synaptophysin in primary hippocampal neurons. Primary
hippocampal neurons were treated with 10 nM testosterone for 1 h, followed by exposure to 5𝜇M oligomeric A𝛽 for 24 h. Neurons were
stained with synaptophysin antibody. (a) Control, (b) 10 nM testosterone for 25 h, (c) 5 𝜇M A𝛽 for 24 h, and (d) 10 nM testosterone for 1 h,
followed by exposure to 5 𝜇M A𝛽 for 24 h. (e) The number of puncta and (f) the fluorescent intensity were analyzed by Image J software as
described in the above section. ∗𝑃 < 0.05 versus control group, #𝑃 < 0.05 versus A𝛽 group. White dot boxes indicate reduced number of
puncta along neurites in A𝛽-treated group.
6 BioMed Research International
C
on
tro
l
(a)
Te
sto
ste
ro
ne
(b)
A
𝛽
(c)
Te
sto
ste
ro
ne
 +
 A
𝛽
(d)
A𝛽
1.25
1
0.75
0.5
0.25
0
Fo
ld
 o
f c
on
tro
l
Control TestosteroneTestosterone
+ A𝛽
Number of puncta of synaptotagmin
##
∗∗
(e)
A𝛽
1.25
1
0.75
0.5
0.25
0
Fo
ld
 o
f c
on
tro
l
Control TestosteroneTestosterone
+ A𝛽
Fluorescent intensity of synaptotagmin
##
∗
(f)
Figure 3: Testosterone attenuated oligomeric A𝛽-induced reduction of synaptotagmin in primary hippocampal neurons. Primary
hippocampal neurons were treated with 10 nM testosterone for 1 h, followed by exposure to 5𝜇M oligomeric A𝛽 for 24 h. Neurons were
stained with synaptotagmin antibody. (a) Control, (b) 10 nM testosterone for 25 h, (c) 5 𝜇M A𝛽 for 24 h, and (d) 10 nM testosterone for 1 h,
followed by exposure to 5 𝜇M A𝛽 for 24 h. (e) The number of puncta and (f) the fluorescent intensity were analyzed by Image J software as
described in the above section. ∗𝑃 < 0.05 versus control group, ∗∗𝑃 < 0.005 versus control group, and ##𝑃 < 0.005 versus A𝛽 group.
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Figure 4: Testosterone attenuated oligomeric A𝛽-induced reduction of synapsin-1 in primary hippocampal neurons. Primary hippocampal
neurons were treated with 10 nM testosterone for 1 h, followed by exposure to 5𝜇M oligomeric A𝛽 for 24 h. Neurons were stained with
synapsin-1 antibody. (a) Control, (b) 10 nM testosterone for 25 h, (c) 5 𝜇MA𝛽 for 24 h, and (d) 10 nM testosterone for 1 h, followed by exposure
to 5 𝜇MA𝛽 for 24 h. (e) The number of puncta and (f) the fluorescent intensity were analyzed by Image J software as described in the above
section. ∗∗∗𝑃 < 0.0005 versus control group, #𝑃 < 0.05 versus control group, and ∗𝑃 < 0.05 versus A𝛽 group. White dot boxes indicate
reduced number of puncta along neurites.
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Figure 5: Oligomeric A𝛽-induced impairment of synaptic vesicle unloading was ameliorated by pretreatment of testosterone. Primary
hippocampal neurons were treated with testosterone or letrozole (aromatase inhibitor) + testosterone, followed by exposure to 5𝜇M
oligomeric A𝛽 for 24 h. Neurons were stained with FM4-64 fluorescent probe. (a)–(d) represent synaptic vesicle uptake FM probe capability.
(a) Control, (b) testosterone 10 nM for 25 h, (c) A𝛽 5 𝜇M for 24 h, and (d) 10 nM testosterone for 1 h, followed by exposure to 5 𝜇M A𝛽 for
24 h. (e–j) represent synaptic vesicle release FM probe capability. (e) Control, (f) testosterone 10 nM for 25 h, (g) A𝛽 5 𝜇M for 24 h, (h) 10 nM
testosterone for 1 h, followed by exposure to 5𝜇M A𝛽 for 24 h, (i) Let 1 𝜇M for 25 h, (j) treatment of 1𝜇M Let, and 10 nM testosterone for
1 h, followed by exposure to 5𝜇M A𝛽 for 24 h. (k) The statistical analysis of FM probe loading fluorescent intensity and (l) the fluorescent
intensity of FM probe unloading were measured by Image J software as described in the above section. ∗∗∗𝑃 < 0.001 versus control group,
∗∗
𝑃 < 0.01 versus A𝛽 group, and ##𝑃 < 0.01 versus A𝛽 group.
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Figure 6: Testosterone attenuated oligomeric A𝛽-induced reduction of heat shock protein in primary hippocampal neurons. Primary
hippocampal neurons were treated with 10 nM testosterone for 1 h, followed by exposure to 5𝜇M oligomeric A𝛽 for 24 h. Neurons were
stained with HSP70 antibody. (a) Control, (b) 10 nM testosterone for 25 h, (c) 5𝜇MA𝛽 for 24 h, and (d) 10 nM testosterone for 1 h, followed
by exposure to 5 𝜇MA𝛽 for 24 h. (e)The fluorescent intensity was analyzed by Image J software as described in the above section. ∗∗𝑃 < 0.01
versus control group; ##𝑃 < 0.01 versus A𝛽 group.
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preserved cytoskeletal protein (MAP-2) and synaptic vesicle
proteins in A𝛽-treated hippocampal neurons. Testosterone
also mitigated A𝛽-induced synaptic exocytosis dysfunction
probably through an estrogenic independent pathway. In
addition, we showed that testosterone treatment attenuated
A𝛽-induced reduction of HSP70. Our data suggest that
testosterone is effective in reducing A𝛽-induced synaptic
dysfunction in rat hippocampal neuron, and this may explain
the importance of physiological dosages of testosterone in the
prevention of AD.
Testosterone is known to modulate synaptic plasticity
and is involved in the maturation of spine [42, 43]. It
has been proved that the hormone can reach the brain
via blood circulation, or it can be synthesized locally in
the hippocampus in a low yet sufficient concentration to
modulate synaptic density and synaptic functions [44, 45].
In our study, we have shown that physiological level of
testosterone was able to attenuate devastating changes in the
synapse. It is interesting to note that testosterone mainly
attenuated changes in the presynaptic compartment (preserv-
ing synaptophysin, synaptotagmin, and synapsin-1) from our
results. Since we did not detect obvious changes between
the control and A𝛽-treated groups for postsynaptic proteins
such as postsynaptic density 95 (PSD-95) (Supplementary
Figure 1, see Supplementary Material available online at
http://dx.doi.org/10.1155/2014/103906), we did not further
investigate the effects of testosterone on the postsynaptic pro-
teins. In the study conducted by Ziehn and colleagues, it was
found that testosterone could restore the excitatory synaptic
transmission and the levels of both pre- and postsynaptic
proteins in amousemodel ofmultiple sclerosis (experimental
autoimmune encephalomyelitis, EAE) [46]. They reported
that testosterone restored the levels of PSD-95 during EAE
and attenuated the atrophy of hippocampus. In another study
conducted by Li and colleagues, testosterone replacement in
castrated mice also restores the decreased level of PSD-95
[42]. These studies suggested that testosterone may preserve
the postsynaptic compartment (spine) and it is likely to have
an effect on PSD-95. It is not clear why testosterone could
not preserve oligomeric A𝛽-induced changes on PSD-95 in
our model. Since the two studies were conducted in animals
in which microglia were present to surround neurons, it is
therefore possible that testosterone has an anti-inflammatory
role to mediate its action on PSD-95 through monitoring the
neighboring microglia [46]. In fact, in our in vitro model,
testosterone is likely to have direct effects on neurons because
the growth of microglia was minimized in our preparation
protocol.
Testosterone can bind to androgen receptors, or it can
be aromatized locally to estradiol and then bind to estrogen
receptors [17]. We found that the application of letrozole
to block the conversion of testosterone to estradiol did
not repress the protective effects of testosterone against
oligomeric A𝛽, as indicated in our FM probe exocytosis
experiment. The results suggested that it is unlikely for
testosterone to elicit its neuroprotective benefits through
activation of estrogen receptors. In fact, our data showed that
cotreatment of testosterone and letrozole further attenuated
A𝛽-induced reduction in FM probe fluorescent intensity.
The results suggest that testosterone per se is able to revert
impairment of presynaptic functions. The next question is
how testosterone modulates different presynaptic proteins.
Classical signaling for testosterone to exert its effects is to
bind to androgen receptor. This may display different heat
shock proteins (HSP), especially HSP70 and HSP90.
HSP70 and HSP90 are molecular chaperone which reg-
ulates the folding of proteins and recognizes misfolded
polypeptides. HSP are closely related to the pathogenesis
of neurodegenerative diseases including AD and Parkinson’s
disease. It was shown in a pilot study that the protein level
of HSP70 was markedly decreased in the olfactory receptor
neurons of subjects with ADwhen compared to age-matched
controls [41]. In another postmortem brain study, the expres-
sion of HSP70 was significantly increased in the temporal
cortex of patients with AD [47]. These findings suggest that
the level of HSP70 might change with stress. In vivo study
supported the protective role of HSP70 in synapse. The
induction of HSP70 prior to heat shock preserved synaptic
performance deficit from subsequent hyperthermia insult
[48].Moreover, overexpression ofHSP70 could suppress AD-
related phenotypes and reduce synaptic loss in a transgenic
AD mice model [49], further indicating the importance
of HSP70 during AD pathogenesis. In our study, we had
demonstrated that A𝛽-induced decrease in HSP70 protein
level was restored in the testosterone treatment group. This
finding is in linewith those reported byZhang and colleagues,
showing that testosterone and estrogen attenuated neuronal
cell death induced by intracellular A𝛽
1−42
. They reported
that testosterone treated group has increased levels of HSP70
and comicroinjection of HSP70 with A𝛽
1−42
blocks the
neurotoxicity of the peptide [27]. The molecular mechanism
underlying HSP70 neuroprotection against oligomeric A𝛽
toxicity is not clear. Previous studies suggested that HSP70
could prevent the translocation of p53 to the nucleus, thus
inhibiting apoptosis [47, 49]; yet it is still uncertain if this
is involved in the observed synaptic changes. One possi-
ble explanation for the observed improvement in synaptic
vesicle release would be the stabilizing effects of HSP70 on
presynaptic protein expression. In fresh pond water snails,
early induction of HSP70 stabilized presynaptic proteins
(syntaxin I, synaptic vesicle protein 2, and synaptotagmin
I) expression and attenuated hypoxia-induced motor and
sensory impairment [50]. HSP70 may also confer protec-
tion to the presynaptic compartment by stabilizing calcium
concentration and calcium influx. It has been reported that
HSP70 can interact with the cytosolic loop of CaV2.3 R-type
voltage-gated calcium channel [51].The interaction of HSP70
and calciumchannelmight be important for the prevention of
calcium overload during stress condition, thus contributing
to better synaptic transmission [52].
In summary, we have shown that physiological concen-
trations of testosterone protect hippocampal neurons from
oligomeric A𝛽-mediated synaptic toxicity and in the same
time increase the expression of HSP70 in these neurons.
Given that the use of testosterone replacement therapy is
still controversial with safety concern [53], understanding the
downstream effectors of testosterone in the AD brain may
BioMed Research International 11
be helpful for the identification of potential pathway specific
neuroprotective agents.
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